Market Advisors, Inc. Issues Report on Weikang Bio-Technology Group Company, Inc.

/ Source: GlobeNewswire

LINCOLN, Neb., Jan. 19, 2011 (GLOBE NEWSWIRE) -- A research update report has been issued by Market Advisors, Inc. "Fundamental Analysis for Today's Investments" on Weikang Bio-Technology Group Company, Inc. (OTCBB:WKBT). To view the report, please go our web site at .

According to the report, The Company expects to announce the fiscal year ended 12-31-10 net revenues of $77.8 million, which is a 64% increase from last year's $47.5 million reported for fiscal year 2009. WKBT expects to report net income of $31.2 million, which is a 100% increase from $15.6 million for fiscal 2009, and earnings per share of $1.04. Our intermediate term target price is $6.05.

About Weikang Bio-Technology Group, Company, Inc.

WKBT is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM) and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals.

About Market Advisors, Inc.

Officers of Market Advisors, Inc. have been in business since 1983 and have provided stock market research for their clients since 1985. Company officials have often been quoted in a wide array of financial publications such as the Wall Street Journal, Investors Business Daily, Barron's, Forbes Magazine and The Dick Davis Digest to name a few.

The information and opinions in this analyst report were prepared by Market Advisors, Inc. and Associates (located in Nebraska) who does receive fees for services including preparation of this report. This is not an offer to buy or sell securities nor should this report be construed as investment advice. Information or statements are subject to numerous risks and uncertainties that cause such statements not to prove accurate. Market Advisors, Inc. does not disseminate, nor is it liable for the dissemination by any third party of this analyst report

For further corporate information from WKBT, Inc, please visit: 

CONTACT: Weikang Bio-Technology Group Co., Inc. Investor Relations Phone: (310)-819-2948 Market Advisors: Doug Wetzel Phone: (308) - 385-4991